In ovo vaccination against Marek's Disease Virus (MDV) is a common practice in more than 85% of broilers produced in the US. DNA vaccines represent a new tool to prevent infectious diseases in many species, including poultry. An in ovo delivery system for plasmid DNA vaccines is described in which we evaluate the route of delivery (air cell vs amniotic cavity), transfection reagent (IFA+DMSO v s polyethylenimine), dose of plasmid DNA (1 to 100 µg/egg) and the nature of humoral immune responses. A plasmid DNA (CMV-EGFP-BGH) construct expressing Enhanced Green Fluorescent Protein (EGFP) under cytomegalovirus (CMV) immediate early promoter was used to optimize the route of delivery and formulation for in ovo DNA vaccination. A plasmid expressing the hemmagglutinin-neuraminidase (HN) gene o f Newcastle disease virus (pIRES-HN-EGFP) was used to evaluate five different dosages of DNA and the humoral immune responses after in ovo vaccination. Higher expression of EGFP and hatchability were obtained when 18-day-old embryos were inoculated through the amniotic cavity using a cationic lipid adjuvant containing polyethylenimine (PEI-ExGen®). Transgene expression was observed even when low amounts of plasmid DNA were used (1 µg/egg). A dose-dependent response was observed with plasmid DNA concentrations of 1, 10, 25, 60 and 100 µg/egg. Better responses were detected when embryos were inoculated with 60 µg of plasmid DNA. Detectable humoral responses were observed as measured by ELISA and isotope-ELISA assays.
Introduction
In the 1990s, an entirely new type of vaccine (DNA vaccines) was first described (Wolff et al., 1990; Robinson et al., 1993; Ulmer et al., 1993) . These new vaccines used naked plasmid DNA to express foreign proteins in the host. DNA vaccines are specially modified bacterial plasmids that usually have a n Escherichia coli origin of replication, an antibiotic resistant gene and eukaryotic promoter that drives the expression of the target gene, a target gene and a polyadenylation signal sequence. The target gene is usually an antigenic protein from a pathogenic infectious organism. The plasmid DNA is commonly delivered either by intramuscular injection or with the use of a gene-gun that forces the DNA into epidermal cells. Since these initial reports on this novel vaccine technology, DNA vaccines have been successfully used to i mmunize a number of different animal species against a multitude of infectious agents (Scholz et al., 1993; Fynan et al., 1993; Sakaguchi et al., 1996; Corr et al., 1996) . DNA vaccines have also been successfully used in poultry to immunize against several pathogens (Fynan et al., 1993; Robinson et al., 1993; Sakaguchi, 1996) . Many of these experimental procedures used large amounts of plasmid DNA in several applications. These methods employ impractical delivery systems, such as by gene-gun or intramuscular injections, which currently are not suitable for administration to large numbers of birds in a cost effective manner. In order to be suitable for poultry, DNA vaccines have to be easily administered to large numbers of animals at the same time. The air cell route for in ovo delivery of plasmid DNA was examined previously and protein expression was demonstrated in the embryo using the Chloramphenicol Acetyl Transferease (CAT) reporter gene (Oshop et al., 2003) . Several eukaryotic expression vectors with different promoters have been evaluated and all avian studies reported higher levels o f expression when using human cytomegalovirus immediate early promoter/enhancer (CMV) (Oshop et al., 2003; Kapczynski et al., 2002; Suarez et al., 2000; Akiyama et al., 1994; Scholz et al., 1993) . Plasmid DNA can be easily degraded after delivery by host endonucleases (Lewis and Babiuk, 1999) . In order to protect and enhance plasmid DNA expression, many attempts to develop an adjuvant have been made. Calcium phosphate, diethylaminoethyl (DEAE) dextran, CMV-EGFP-CAT-BGH, a gift from Dr. Subbiah 25% sucrose, polybrene (hexadimethrine bromide) and Elankumaran . Cloning procedures two cationic lipids (lipotaxi and lipofectin) were evaluated were carried out essentially as described (Sambrook et as adjuvants to an avian influenza DNA vaccine when al., 1989) . Briefly, the CAT gene was removed b y injected into the muscle of one-day-old chicks. Lipotaxi digestion with ApaI and NotI restriction enzymes. The and lipofectin induced better antibody responses DNA fragment was excised from a 1% agarose gel and (Suarez et al., 2000) . In addition, two possible adjuvants re-ligated. E. coli (DH5") were transformed and for in ovo DNA vaccination, neutral lipid Incomplete recombinants were plated on ampicillin plates. Plasmid Freund's Adjuvant (IFA) mixed with dimethyl sulfoxide DNA was prepared and purified using endotoxin-free (DMSO) and a cationic lipid (LipofectAmine Plus®), were silica column kits (Qiagen, Inc., Valencia, CA) as per also evaluated. Better results were obtained by IFA manufacturer instructions. The plasmid DNA preparation mixed with 50% DMSO (v/v) (Oshop et al., 2003) . Another was checked on 1% agarose gel (w/v) for genomic DNA study done in vitro suggests the use of PEI (ExGen®) to or RNA contamination. The plasmid concentration was obtain optimal transgene expression (Heckert et al., determined by spectrophotometer reading (260 nm). 2002).
The plasmid DNA was frozen at-20°C to protect it from Another important aspect to be evaluated is the dose of degradation by endonucleases. plasmid DNA required to obtain high protein expression.
The last two studies utilized the pIRES-EGFP vector in Earlier studies (Oshop et al., 2003; Suarez et al., 2000) which the HN gene of NDV (Beaudette strain) was observed a dose-dependent response using one-dayinserted to generate the pIRES-HN-EGFP plasmid. old chicks and 18-day-old embryos, respectively. Suarez
Briefly, Vero cells were infected with NDV at a Multiplicity and co-workers used 10, 50, 100 and 250 µg of pCIof Infection (MOI) of 0.01. Three days after infection, viral neoHA/bird intramuscularly. A maximum response was RNA was extracted and used as template for RT-PCR. observed when 100 µg of plasmid was used (Suarez et The coding sequence of HN consisting of 2265 base al., 2000) . In ovo inoculation studies by Oshop and pairs was amplified using two specific primers that collaborators, reported better responses using 60 µg of introduced BglII and SacII restriction enzyme recognition plasmid (Oshop et al., 2003) .
sites (respectively underlined) at the 5' and 3' end of the Several studies in recent years addressed the nature of NDV HN antigenomic RNA. Primers used were: forward plasmids, such as promoter and polyadenylation 5'-AAGATCTATGGACCGCGCAGTTAGCCAAGTTG-3' and signals (Kapczynski et al., 2002; Oshop et al., 2003;  reverse 5'-A C C G C G G T A C T A A C C A G A C C T G Heckert et al., 2002; Suarez et al., 2000) . Several routes GCTTCTCTAAC-3'. RT-PCR product was excised from for optimal plasmid DNA delivery, such as intramuscular 1% agarose gel using a QIAquick gel extraction kit Fodor et al., 1999) , transcutaneous (Qiagen Inc., Valencia, CA). The PCR product was and in ovo (Oshop et al., 2003;  ligated into a pCRII-TOPO vector using the Topo cloning Kapczynski et al., 2002) were examined. There are few kit (Invitrogen). After ligation, E. coli cells were reports regarding the dose of plasmid DNA vaccine for transformed and white colonies bearing the inserted HN optimum transgene expression and protection efficacy gene were selected for plasmid preparation. Plasmid (Oshop et al., 2003; Heckert et al., 2002; Suarez et al., was digested with BglII and SacII restriction enzymes. 2000; Sakaguchi et al., 1996) . HN gene fragment was recovered after gel purification There are only a few studies that address the issue of in and then ligated between BglII and SacII sites of pIRESovo delivery of DNA vaccines in chickens. Therefore, the EGFP vector (Fig. 1 ). E. coli cells were transformed and present study was designed to address several the recombinants selected after plating. The resulting parameters to optimize in ovo DNA vaccination i n plasmid was designated pIRES-HN-EGFP. The inserted chickens. This study has several objectives. We will DNA was sequenced to confirm the identity of the HN compare the air cell route previously examined for gene. Large amounts of purified, endotoxin-free plasmid plasmid DNA vaccination and the amniotic cavity, the were obtained from Aldevron, Inc. (Fargo, ND). route routinely used by the poultry industry to deliver Marek's vaccine. We also propose to determine the In vitro transfection: The plasmid CMV-EGFP-BGH was most efficient transfection reagent for in ovo DNA evaluated in vitro using HD11 (avian macrophage cell vaccines (IFA+DMSO vs PEI-ExGen®). Another important line) cells to test its transfection capability as described aspect addressed in this chapter is the dose of DNA . Briefly, HD11 cells were vaccine for in ovo inoculation. We also evaluate the transfected with 5 µg of plasmid DNA using humoral immune responses of DNA vaccine expressing LipofectAmine (Invitrogen). After 24 h incubation, cells the HN gene of NDV, after in ovo delivery.
were examined under a Nikon Eclipse TE epifluorescent
Materials and Methods

Construction of plasmid DNAs:
To evaluate route and formulation for in ovo DNA delivery, we used a plasmid microscope to detect EGFP. The p lasmid pIRES-HN-EGFP (5 µg) was used t o transect Vero cells using Lipofectin (Invitrogen, Grand Islands, NY). Protein expression was observed by to induce death by hypothermia. Tissues such as liver, NDV-HN gene was inserted in the Multiple lung, spleen, muscle, intestine and heart were collected. Cloning Sites (MCS). Independent EGFP Tissues were placed in TissueTek OCT Compound expression was possible due to the presence of (Sakura, Inc.) and snap frozen in liquid nitrogen. The Internal Ribosomal Entry Site (IRES) downstream samples were then stored at-70°C until processing. of MCS Frozen tissues sections were cut at 8 µm thickness with immunostaining techniques. Briefly, after transfection for 20 min and mounted into glass slides with Vero cells were washed three times with Phosphate PBS/glycerol (v/v). Tissues samples were then Buffered Solution (PBS) and fixed with acetone and microscopically examined under a UV light (488 nm methanol (v/v) for 20 min. Vero cells were washed twice excitation) at 40, 100, 400X magnification. and incubated with polyclonal chicken anti-NDV antibody (1:20) for 1.5 h at RT. Cells were then washed three Experiment 2: Having determined the most effective times and goat anti-chicken IgG peroxidase labeled route for in ovo plasmid delivery as well as formulation, antibody (1:50) was added and plates were further this experiment was designed to evaluate the dosage of incubated at RT for 30 min. Cells were washed three pIRES-HN-EGFP DNA to obtain higher levels of protein times and 200 µl/well of Trueblue® (Kirkegaard and expression. Plasmid DNA was mixed with ExGen® in Perry Lab., Gaithersburg, MD) peroxidase substrate was five different dosages (1, 10, 25, 60, 100 µg/egg) and added. After 15 min, Trueblue® excess was rinsed and injected into the amniotic cavity. Fifteen eggs were used cells were examined under the microscope.
per d ose tested. One control group was used, Experiment 1: In order to determine route and pIRES-EGFP). Right before hatch, all eggs were placed formulation to be used for plasmid DNA delivery, five in the refrigerator to induce death by hypothermia. groups (of at least 10 eggs each), were inoculated into Spleens were removed aseptically from each embryo. the air cell and amniotic cavity with 60 µg/egg of CMV-EGFP-BGH. A preliminary trial to test the amniotic cavity Experiment 3: This study was designed to evaluate delivery technique was performed using Indian ink. After immune responses elicited by in ovo injection of pIRESdye inoculation, embryos were chilled and opened to HN-EGFP vaccine construct. Eggs were inoculated with inspect the site of inoculation. For air cell inoculations, 60 µg/egg of plasmid DNA mixed with ExGen® by the pre-trials were considered unnecessary. All amniotic cavity as described in Experiment 1. Group 1 embryonated eggs used in these experiments were was inoculated with pIRES-HN-EGFP; group 2 received from white leghorn hens, 18 days of embryonation, SPF the plasmid DNA backbone control and a third group (SPAFAS Inc, Norwich, Ct., USA) and were incubated at was left un-inoculated. Eggs were sealed and incubated 100ºF with 60-80% humidity, as indicated by the until hatch. All feather-dried hatched chicks were thermometer (dry bulb) and hygrometer (wet bulb), transferred directly from the hatcher to biological level 2 respectively. For either route of inoculation, a small hole (BL2) animal facility in Avrum Gudelsky Veterinary Center was made in the large end of the egg. The air cell inoculation was performed by dropping the plasmid DNA formulation on top of the chorioallantoic membrane, using a 25 gauge, 2.5 cm needle and only half of the needle length was allowed to penetrate the eggshell. Inoculations into the amniotic cavity were performed using a 23 gauge, 2.5 cm needle, accordingly t o preliminary trials described previously. The ExGen® formulation consisted of 60 µg of plasmid CMV-EGFP-BGH diluted into sterile glucose solution (5%) and six equivalents of the cationic polymer gene delivery reagent (ExGen®500 in vivo transfection, MBI Fermentas). The second formulation tested (Oshop et al., 2003) , consisted of 60 µg of plasmid DNA combined with IFA, forming a mixture of 50 µL and mixed vigorously. The same amount of DMSO (Sigma, USA) was added and the mixture was sonicated. One control group consisted of 10 eggs that were un-inoculated. After inoculation, all eggs were sealed with tape and reLeitz HM-500 Cryostat, air-dried at RT, fixed in acetone consisting of plasmid DNA without HN insert (backbone and h oused in isolation chambers with ad libitum NDV (10D11 and 15C4) were diluted (1:200) and added access to feed and water. At three weeks of age, all to each well. After 30 min incubation and five washes, three groups were sampled for serum and tears. Tears goat-anti-mouse peroxidase (Kirkegaard and Perry were collected as described (Elankumaran et al., 1996) Laboratories Inc., Gaithersburg, MD) was added (100 by applying a pinch of salt to each eye. At five weeks of µL). The plate was then incubated for 30 min at RT and age all birds were anesthetized using isoflurane and 3-6 washed five times. The substrate TMB (100 µL) mL of blood was collected by cardiac puncture. The (Kirkegaard and Perry Laboratories Inc., Gaithersburg, birds were then humanely euthanized.
MD) was then added to each well and incubated at RT
Flow cytometry analyses:
To determine dosage o f addition of 100 µL of sulphuric acid (2M). Absorbances plasmid DNA needed for high protein expression, the were read at 450 nm (reference wavelength of 550 nm). spleens from birds inoculated with pIRES-EGFP were
The S/P ratios were calculated for each sample. macerated and filtered through sterile 70 µm nylon cell HI w as performed using 4 hemagglutination units strainers (Falcon, Becton Dickinson Labware, NJ). Cells (HAU). Briefly, serum samples were two-fold diluted in Vwere washed three times with 5 mL of sorter buffer botton-96 well plates and incubated with 4 HAU of the (Hanks balanced salt solution w/o phenol red, 3% FBS, titered antigen (NDV) at RT for 30 min. After incubation, 1% sodium azide) for 5 min, 42 x g at 4ºC and 25 µL of 1% chicken RBC's were then added to each resuspended in sorter buffer. Viable cells were counted well. After 40 min incubation, the HI titer was determined by trypan blue dye exclusion method. A cocktail of NDV as the highest dilution of serum causing inhibition of monoclonal antibodies (62.5 µL of MAb10D11 and 62.5 hemagglutination. µL of MAb 15C4 in 12.37 mL of sorter media) was added (100 µL) to the cells and incubated on ice for 40 min.
Statistical analysis: Results obtained from Experiment After two washes, cell pellet was resuspended in 2 mL 1, 2 and 3 were statistically analyzed using the Student of sorter buffer and 100 µL of goat anti-mouse t-test (Statistix, version 7.0). Experimental group means IgM+IgG+IgA R-phycoerythrin (PE) labelled (1:500)
were considered significantly different from each other if (SouthernBiotech, Inc., Birmingham, AL) was added.
p<0.05. Cells were incubated on ice for 30 min, washed twice and resuspended in 1 mL of sorter buffer. Analyses were performed using an EPICS XL-MCL flow cytometer.
Serology:
Humoral immune responses to HN protein were measured by ELISA (Synbiotics, San Diego, CA), isotope ELISA and HI. To verify specific antibody isotope (IgG, IgA and IgM), serum and tear samples were analyzed by a sandwich ELISA as described . Briefly, ninety-six well ELISA plates of high adsorption capability (Nunc Maxisorb Immunoplate) were coated with affinity purified goat-antichicken IgG, IgA, or IgM (Bethyl Laboratories, Inc.) antibodies (100 µl/well) diluted 1:200 i n carbonate/bicarbonate buffer (0.1M pH 9.6). The plate was then incubated at 37°C for 1 h. After five washes with PBST (PBS, 0.05% Tween-20) plates were dried and blocked for 1 h at RT with 1% BSA in PBST. Serum and tear samples were diluted 1:50 in dilution/blocking buffer (Kirkegaard and Perry Laboratories Inc., Gaithersburg, MD) and 100 µL of each sample was added to the appropriate wells. Each sample was run in duplicate. Anti-NDV chicken polyclonal serum (1:50) was used on each plate to serve as positive control. Normal chicken polyclonal serum (1:50) was diluted and used as a negative control. The plates were then incubated at RT on a plate shaker for 1 h. After incubation, plates were washed five times and incubated with NDV (1:200) at RT for 30 min. Each sample was tested with each antibody isotope, separately. Monoclonal antibodies to for 10 min. The color reaction was terminated by the
Results
In vitro expression:
In order to confirm that CMV-EGFP-BGH p lasmid expressed the reporter gene (EGFP), HD11 avian macrophage cells were transfected and observed under UV light. Our transfection experiments demonstrated the expression of EGFP gene by this construct (Fig. 2) . HN expression by pIRES-HN-EGFP was confirmed by the transfection of Vero cells and immunostaining technique (Fig. 3) .
In vivo EGFP expression after in ovo injection: Tissue distribution of EGFP expression is shown in Fig. 4 . EGFP expression was detected in all tissues examined. The only two exceptions were the spleens of embryos inoculated by the air cell with ExGen® and intestine of embryos inoculated through either route with IFA+DMSO. Significantly (p<0.05) higher expression was observed in the muscle of embryos inoculated by the amniotic cavity using ExGen®. In this group, the percentages were 64, 40, 14, 25, 35 and 12% in the muscle, lungs, liver, spleen, heart and intestine, respectively. Lower percentages of expression were observed in tissues from embryos inoculated by the air cell using either formulation. Also, lower percentages of expression were observed when plasmid DNA was delivered into the amniotic cavity using IFA+DMSO. Muscle and lung tissues consistently showed higher level of expression irrespective of the route or formulation used. With IFA+DMSO formulation, 48 and 52% of embryos pipped when inoculated through the amniotic or air cell route, respectively. In contrast, eggs inoculated with ExGen® formulation for DNA delivery, 93% and 97% of the eggshells pipped, when the air cell and amniotic cavity routes were used. These results indicate that were transfected with 5 µg of plasmid using Embryos were inoculated through the amniotic cavity with 1, 10, 25, 60 and 100 µg/egg of pIRES-HN-EGFP DNA mixed with PEI ExGen®, whereas, the control group consisted of 6 0 µg/egg of pIRES-EGFP DNA. The spleens were collected prior to hatch and processed for flow cytometry analyses. Bars represent the standard deviation per group analyzed. No significant differences were observed among embryos inoculated with 10, 25 and 60 µg/egg of plasmid DNA
(1 µg/egg) are able to transect the embryo resulting in protein expression. The backbone plasmid results (1.95%) were considered background. We also observed a dose-dependent response inferring that higher amounts of DNA do not necessarily result in higher expression. IgM. Fig. 6 shows the mean of each treatment group. At 5 weeks post-vaccination, two birds (2/6) that received the pIRES-HN-EGFP plasmid were considered positive as measured by commercial ELISA (data not shown). All tear and serum samples analyzed by Hemagglutination Inhibition (HI) test were negative at all collection periods.
Discussion
Previous research has indicated in ovo DNA vaccines can be delivered into the air cell of ECE when encapsulated by neutral lipids such as IFA and DMSO (Oshop et al., 2003) . We obtained similar results regarding EGFP expression when using the air cell route. Hatchability rates of 52-57% were also similar. In addition, the air cell was compared with the amniotic cavity route, which is routinely used for Marek's in ovo vaccination of chickens in the poultry industry. When the plasmid DNA was delivered by the amniotic cavity a significantly higher percentage of tissues expressed EGFP.
Wakenell and co-workers evaluated the air cell route for delivery of Marek's vaccine in ovo. The authors reported a lack of vaccinal response caused by the inability of the measured by AC-ELISA (Oshop et al., 2003) . These virus to cross the air cell membrane (Wakenell et al., 2002) . On the other hand, Oshop and co-workers, suggest that DMSO may increase permeability through membranes, thus enhancing plasmid DNA up take by the embryo (Oshop et al., 2003) . Considering that plasmid DNA does not replicate as MDV and thus, its capacity to cross embryos membranes have to b e mediated by a carrier such as DMSO. However, we obtained lower level of expression through the air cell. In addition, a dramatic decrease in hatchability of embryos vaccinated with IFA and DMSO formulation (52%) was observed when compared to ExGen® (97%). In our studies, embryos inoculated with DMSO that had died before hatch exhibited evidence of hepatic toxicity (data not shown). Affected livers were larger with severe congestion and hemorrhages. The average hatchability rate in the poultry industry is 83%; lower rates represent a large loss in productivity. The results obtained in our studies using ExGen® as a vaccine adjuvant for in ovo inoculation were excellent. In addition, a consistent expression of the reporter gene in the muscle and lungs of embryos inoculated by either route or formulation was observed. For these reasons, it was decided to use the amniotic route and ExGen® to deliver plasmid DNA in the vaccine experiments. It is also important to point out that the cost of this cationic lipid (ExGen®) is very high to be considered for commercial applications. High titers of IBDV in the lungs of embryos vaccinated by in ovo injection were reported, suggesting that this organ may play a main role in vaccine spread and protection (Sharma, 1986) . In this previous experiment, muscle as well as lungs had the highest expression rates of the reporter gene, independent of route o r formulation used (64 and 40%, respectively). Another important aspect of in ovo plasmid DNA delivery was addressed in Experiment 2. Five different dosages of p lasmid DNA (1, 10, 25, 60, 100 µg/egg) were evaluated for protein expression. A prior report observed a dose-dependent response in 18-day-old embryos and better responses were obtained using 60 µg/egg o f plasmid DNA (Oshop et al., 2003) . Flow cytometry results also showed a dose-dependent response t o plasmid DNA using 1, 10, 25 and 60 µg/egg, but expression efficiency decreased with a dose of 100 µg/egg. The highest percentage of HN labelled cells was seen in the groups inoculated with 10 and 2 5 µg/egg (9.63% and 8.72%, respectively). However, these groups also had a high standard deviation that suggests inconsistent results. For this reason, we decided to use 60 µg of plasmid DNA/egg in future experiments because there were no significant differences among these three groups (10, 25 and 60 µg/egg). In addition, the 60 µg/egg group presented a much lower standard deviation (1.36). Similar results were observed by Oshop et al. (2002 Oshop et al. ( , 2003 when CAT protein expression was studies also show that small amounts of plasmid DNA (1 µg/egg) are able to transect the embryos resulting in protein expression (HN) and that large amounts of DNA may have a detrimental effect on transfection efficiency. The immune responses induced by in ovo inoculation of plasmid DNA pIRES-HN-EGFP was measured by ELISA, isotope ELISA and HI. A humoral response was not detected until 5 weeks of age. Few birds seroconverted as measured by commercial ELISA. Considerable IgM levels were detected by the isotope ELISA, indicating a primary immune response. All samples were negative for IgA suggesting that DNA vaccines delivered in ovo may not stimulate mucosal immunity. Several important factors for in ovo DNA vaccine delivery were considered in this study. Using a well-studied promoter (CMV) (Oshop et al., 2003; Suarez, 2000; Kodihalli et al., 1997) two routes, two formulations and five dosages for DNA vaccine delivery were evaluated. The humoral immune responses against plasmid DNA that encodes the HN gene from NDV were also evaluated. In the next study, these findings will b e applied in the development of a DNA vaccine against IBDV.
